GlassScriptPhysician profile
Catherine R Weir
NPI 1922635077
$6,403.38
in general payments reported to CMS, 2019-2025
47 companies · $2,511 in 2025
The $2,511 reported for 2025 was more than what 98% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,327 · 2024: $2,566 · 2025: $2,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,186 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,185.50 |
| Education | $217.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $655.98 | 2023-2025 | |
| Sobi, INC | $446.49 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $431.90 | 2023-2025 | Fotivda |
| Janssen Biotech, INC. | $415.12 | 2023-2025 | Imbruvica, Darzalex, Tecvayli |
| Pharmaessentia USA Corporation | $332.21 | 2023-2025 | Besremi |
| Daiichi Sankyo INC. | $310.80 | 2023-2025 | Vanflyta, Enhertu, Datroway |
| Lilly USA, LLC | $291.02 | 2023-2025 | Jaypirca, Retevmo, Verzenio |
| Abbvie INC. | $218.19 | 2024-2025 | |
| Eisai INC. | $205.42 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $202.79 | 2024-2025 | Keytruda, Welireg |
| Alexion Pharmaceuticals, INC. | $195.86 | 2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $195.57 | 2024-2025 | |
| Stemline Therapeutics INC. | $183.65 | 2023-2025 | Orserdu, Elzonris |
| Astrazeneca Pharmaceuticals LP | $173.75 | 2023-2025 | Imfinzi |
| Regeneron Healthcare Solutions, INC. | $155.70 | 2024-2025 | Libtayo |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $142.28 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.25 | 2024-2025 | Ninlaro, Iclusig, Fruzaqla |
| Beone Medicines USA, INC. | $119.64 | 2025 | Tevimbra, Brukinsa |
| Amgen INC. | $110.93 | 2023 | Kyprolis |
| Tersera Therapeutics LLC | $107.70 | 2023-2025 | Zoladex, Xermelo |
| E.R. Squibb & Sons, L.L.C. | $104.60 | 2024 | Opdivo |
| Incyte Corporation | $101.07 | 2023-2024 | Jakafi, Monjuvi |
| Taiho Oncology, INC. | $90.26 | 2024 | |
| Agios Pharmaceuticals, INC. | $86.84 | 2023-2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $82.96 | 2024 | Qinlock |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.27 | 2025 | |
| Iovance Biotherapeutics, INC. | $81.34 | 2025 | Amtagvi |
| Genentech USA, INC. | $79.52 | 2023-2025 | Phesgo, Kadcyla, Rozlytrek |
| Foundation Medicine, INC. | $72.08 | 2023 | |
| Pfizer INC. | $67.13 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $63.02 | 2024-2025 | |
| Boston Scientific Corporation | $58.12 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Coherus Oncology, INC. | $53.54 | 2025 | Loqtorzi |
| Adc Therapeutics America, INC. | $34.96 | 2025 | |
| Syndax Pharmaceuticals, INC. | $33.00 | 2025 | |
| Genmab U.S., INC. | $31.24 | 2024 | Epkinly |
| Apellis Pharmaceuticals, INC. | $31.20 | 2023 | Empaveli |
| Caris Mpi, INC. | $29.83 | 2025 | Mi Cancer Seek |
| Glaxosmithkline, LLC. | $26.61 | 2025 | Ojjaara |
| Mirati Therapeutics, INC. | $26.26 | 2023 | Krazati |
| Immunocore Limited | $22.95 | 2024 | Kimmtrak |
| Array Biopharma INC | $21.87 | 2024 | Mektovi, Braftovi, Xalkori |
| Accord Healthcare, INC. | $20.61 | 2023 | |
| Tempus Ai, INC | $18.66 | 2024 | |
| G1 Therapeutics, INC. | $16.68 | 2023 | Cosela |
| Csl Behring | $16.55 | 2024 | Idelvion, Afstyla |
| Shorla Oncology INC. | $14.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.